In the article by Hanania et al., in Pulmonary Pharmacology &Therapeutics, vol. 21, (2008), pp. 134-141, entitled, "The safety and effectsof the beta-blocker, nadolol, in mild asthma: An open-label pilot study," mildasthmatics were treated for 9 weeks. All subjects tolerated the drug, and 8of 10 subjects experienced a clinically meaningful, dose-related, reduction inairway hyper-responsiveness.
Advertisement
"To our knowledge, this is the first peer-reviewed publication of aclinical trial testing a beta-blocker for the treatment of asthma," commentedRichard Bond, PhD, Scientific Founder of Inverseon. "These results lay thegroundwork for continuing safety and efficacy studies for a drug that isnormally withheld from asthmatics. A similar story played out 10 years ago incongestive heart failure where certain blocker drugs that were oncecontraindicated are now on the market as the best drugs we have ever had atdecreasing mortality in heart failure."
Advertisement
"From receptor theory to animal data and now to clinical data theInverseon approach is very consistent. In our animal asthma models chronicdosing of beta inverse agonists -- which are a subset of beta blockers --resulted in up-regulation of lung beta receptors, while reducing inflammationand airway hyper-responsiveness. The fact that we are seeing some of thesesame changes in human asthmatic subjects is exciting and suggests we may havea way to counteract some of the negative aspects of long-acting beta-agonistsand steroids when used in combination with INV102. The data also supportsInverseon's reformulation program for oral controlled-release INV102,"commented William J. Garner, MD, Chairman of Inverseon.
About Inverseon, Inc.
Inverseon's product development programs target significant unmet medicalneeds and major market opportunities in chronic pulmonary diseases such asasthma, COPD and pulmonary hypertension. Inverseon was founded based on theoriginal work of Prof. Richard Bond of the University of Houston. ProfessorBond termed the effects "Paradoxical Pharmacology," based on the divergence ofacute versus chronic effects of certain drugs in chronic diseases. Forfurther information, please visit Inverseon's website athttp://www.inverseon.com.
Forward-Looking Statement
This press release may contain forward-looking statements. In some cases,you can identify forward-looking statements by terminology such as "may,""will," "should," "expect," "plan," "anticipate," "believe," "estimate,""predict," "potential" or "continue," the negative of such terms, or othercomparable terminology. These statements are only predictions. Although webelieve that the expectations reflected in the forward-looking statements arereasonable, such statements should not be regarded as a representation by theCompany, or any other person, that such forward-looking statements will beachieved. We undertake no duty to update any of the forward-lookingstatements, whether as a result of new information, future events, orotherwise. In light of the foregoing, readers are cautioned not to placeundue reliance on such forward-looking statements.
This release was issued through eReleases(TM). For more information,visit http://www.ereleases.com.Contact: William J. Garner, MD [email protected] http://www.inverseon.com (212) 222-1188
SOURCE Inverseon, Inc.
